AcelRx Pharma (ACRX) Tops Q3 EPS by 20c

AcelRx Pharma (NASDAQ: ACRX) reported Q3 EPS of ($0.08), $0.20 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $120 thousand versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery